FDA Approves BUPRENORPHINE — Sun Pharmaceutical Industries, Inc.

Sun Pharmaceutical Industries, Inc. announced the approval of its generic buprenorphine hydrochloride sublingual tablets to market, providing a new affordable alternative in the growing opioid addiction treatment space. The launch is expected to capitalize on trailing patent expiration, offering significant competition to branded formulations designed for the management of moderate to severe pain.